Another aryl sulfonamide-based derivative, MPT0B390, transcriptionally upregulates TIMP3 levels in colon cancer cell lines and HUVEC by inhibiting the expression of the enhancer of zest homolog 2 (EZH2, a histone methyltransferase) [46]. Here, EZH2 is linked to malignant colon neoplasm.